Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 9, 2021

Primary Completion Date

January 31, 2025

Study Completion Date

December 31, 2025

Conditions
Parkinson DiseaseMild Cognitive ImpairmentMemory Impairment
Interventions
DRUG

Levetiracetam

Levetiracetam is currently approved in Australia and the U.S.A. for epilepsy. We will be providing levetiracetam in capsule form, 125mg levetiracetam in each capsule.

DRUG

Placebo

Placebo intervention will be maize-starch filled capsules with identical physical features to the active capsules.

Trial Locations (1)

4029

RECRUITING

University of Queensland Centre for Clinical Research, Brisbane

All Listed Sponsors
collaborator

Queensland University of Technology

OTHER

collaborator

Johns Hopkins University

OTHER

collaborator

Cleveland Clinic Lou Ruvo Center for Brain Health

UNKNOWN

collaborator

Royal Brisbane and Women's Hospital

OTHER_GOV

lead

The University of Queensland

OTHER